TargetBeta
TERT
telomerase reverse transcriptase · also TRT, TP2, TCS1, hEST2 · Telomerase holoenzyme subunits
2 programs in company-led studies act on TERT, from 2 companies: 0 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| imetelstatrule | Geron | phase 4 | 164 running | – | ChEMBL |
| Anti-TERT/Anti-CD3 T-cell Engager CBX-663rule | Crossbow Therapeutics | phase 1 | 11 running | CD3E | NCIt |
Also acted on by the same programs
Conditions their studies are in
- Carcinoma, Non-Small-Cell Lung, 1 program
- Multiple Myeloma, 1 program
- Myelodysplastic Syndromes, 1 program
- Primary Myelofibrosis, 1 program
- Thrombocythemia, Essential, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Feb 2027imetelstat · Geron · phase 4 · NCT05371964
- Jan 2028Anti-TERT/Anti-CD3 T-cell Engager CBX-663 · Crossbow Therapeutics · phase 1 · NCT07779798
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.